Candel Therapeutics ( (CADL) ) has provided an update.
On March 26, 2025, Candel Therapeutics announced positive final survival data from its phase 2a clinical trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer (NSCLC) who were inadequately responding to immune checkpoint inhibitor (ICI) treatment. The trial results showed a median overall survival (mOS) of 24.5 months for patients with inadequate ICI response and 21.5 months for those with progressive disease, significantly exceeding the survival rates of 9.8–11.8 months reported in similar populations treated with standard chemotherapy. The data also highlighted a potential precision medicine approach, with non-squamous NSCLC patients showing improved survival rates and a systemic anti-tumor response. These findings suggest CAN-2409 may offer a new treatment avenue for NSCLC patients with limited options, and the company plans to advance its development program for this therapy.
More about Candel Therapeutics
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer.
YTD Price Performance: -16.57%
Average Trading Volume: 1,233,600
Technical Sentiment Signal: Sell
Current Market Cap: $388.3M
Learn more about CADL stock on TipRanks’ Stock Analysis page.